钙维生素D 复合物单独与联用阿仑膦酸钠在治疗糖皮质激素引起骨量丢失疗效的观察

中国临床药理学与治疗学 ›› 2009, Vol. 14 ›› Issue (3): 332-336.

钙维生素D 复合物单独与联用阿仑膦酸钠在治疗糖皮质激素引起骨量丢失疗效的观察

丁晓凯, 刘毅, 徐玉兰, 林凡, 汪延辉

温州医学院附属第一医院肾内科, 温州325003, 浙江

收稿日期:2008-11-17 修回日期:2008-11-17 发布日期:2020-10-27
作者简介:丁晓凯, 男, 硕士, 研究方向:糖皮质激素性骨质疏松和慢性肾脏病并发症诊治。Tel:13857771492 E-mail:DXK7505 @126.com

Compound of vitamin D and Calcium or combining with bisphosphonates in preventing bone loss induced by glucocorticoid

DING Xiao-kai, LIU Yi, XU Yu-lan, LIN Fan, WANG Yan-fei

Department of Nephrology, the First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325003, Zhejing,China

Received:2008-11-17 Revised:2008-11-17 Published:2020-10-27

摘要/Abstract

摘要： 目的比较钙维生素D 复合物单独应用与联合阿仑膦酸钠在治疗长期使用糖皮质激素造成骨量丢失疗效方面的差异。方法 40 例糖皮质激素引起的骨质疏松或骨量减少的患者, 分别给予单用钙尔奇D 片0.6 g 天(A 组) 及联合阿仑膦酸钠70 mg 周(B 组) 治疗, 观察入选时及治疗6 个月后临床疼痛症状、常规生化指标和定量CT 腰椎骨密度(BMD) 值变化。结果两组患者基线水平的一般特征和治疗后疼痛改善总有效率差异无统计学意义(P >0.05)。A 组治疗后腰椎BMD 值有所下降(P<0.05) ;B 组治疗后腰椎BMD 增加(P<0.01) ;B 组治疗后腰椎BMD 值明显高于A组(P<0.01)。两组患者治疗前后常规生化指标变化相近(P >0.05)。结论糖皮质激素长期应用可引起骨量持续丢失。与单纯服用钙维生素D 复合物相比, 钙维生素D 复合物与二膦酸盐联合能更有效地治疗糖皮质激素长期应用引起的骨量丢失。

关键词: 二膦酸盐, 钙维生素D 复合物, 糖皮质激素, 骨质疏松, 骨量丢失, 定量CT

Abstract: AIM: To compare the effects of vitamin D and calcium compound alone or in combination with alendronate on preventing the loss of bone mineral induced by glucocorticoid. METHODS: 40 cases patients, diagnosed osteoporosis or osteopenia were divided into two groups.Group A were treated with a tablet of Caltrate D 0.6 g d and group B were treated with a tablet of Caltrate D 0.6 g d plus alendronate 70 mg week.The clinical painful symptoms, common biochemical indicators, the bone mineral density (BMD) changes of quantitative CT lumbar vertebra were observed at starting point and after 6 months treatment. RESULTS: There was no significant differences between two groups both in general indexes of basal level and in the total effective rates of pain relieveing.After treatment, the BMD of lumbar vertebra were decreased in group A (P<0.05), which were increased significantly in group B (P<0.01), the BMD of lumbar vertebra in group B was higher than that in group A (P<0.01).The changes of general biochemical indicators showed no difference in two groups before and after treatment (P >0.05). CONCLUSION: Long-term use of glucocorticoid induce loss of bone mineral continually.Compared with treated with compound of calcium and vitamin D alone, combination with alendronate can effectively prevent the loss of bone mineral content induced by long-term use of glucocorticoid.

Key words: alendronate, compound of calcium and vitamin D, glucocorticoid, osteoporosis, bone loss, quantitative CT

中图分类号:

丁晓凯, 刘毅, 徐玉兰, 林凡, 汪延辉. 钙维生素D 复合物单独与联用阿仑膦酸钠在治疗糖皮质激素引起骨量丢失疗效的观察[J]. 中国临床药理学与治疗学, 2009, 14(3): 332-336.

DING Xiao-kai, LIU Yi, XU Yu-lan, LIN Fan, WANG Yan-fei. Compound of vitamin D and Calcium or combining with bisphosphonates in preventing bone loss induced by glucocorticoid[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(3): 332-336.

参考文献

[1] 王义生, 胡新永.糖皮质激素性骨质疏松症的防治研究进展[J].河南医学研究, 2006, 15(2):185-188.
[2] Durieux S, Mercadal L, Orcel P, et al.Bone mineral density and fracture prevalence in long-term kidney graft recipients[J].Transplantation, 2002, 74(4):496-500.
[3] Yood RA, Harrold LR, Fish L, et al.Prevention of glucocorticoid induced osteoporosis[J].Arch Intern Med, 2001, 161(5):1322-1327.
[4] 中华医学会骨质疏松和骨矿盐疾病分会.糖皮质激素性骨质疏松症诊疗指南(讨论稿) [J].中华全科医师杂志, 2006, 5(8):460-461.
[5] 李大成, 姜维平, 黎本丰, 等.QCT 骨密度测量的准确性试验方法和意义[J].中国骨质疏松杂志, 2003, 9(3):217-219.
[6] Homik J, Suarez-Almazor ME, Shea B, et al.Calcium and vitamin D for corticosteroid induced osteoporosis[J].Cochrane Database Syst Rev, 2000, 10(2):952-957.
[7] 万学峰, 牛文光, 惠艳.糖皮质激素性骨质疏松的治疗进展[J].临床荟萃, 2004, 19(18):1075-1077.
[8] Krieg MA, Seydoux C, Sandini L, et al.Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study [J].Osteoporosis Int, 2001, 12(2):112-116.
[9] Porthouse J, Cockayne S, King C, et al.Randomised controlled trial of supplementation with calcium and cholecalciferol (vitamin D3) for prevention of fractures in primary care[J].BMJ, 2005, 330(5):1003-1006.
[10] 张俊, 葛宁, 黄晓丽, 等.骨质疏松症的药物治疗评价[J].中国实用内科杂志, 2006, 26(4):313-315.
[11] Pols HAP, Felsenberg D, Hanle DA, et al.For the fosamax international trial study group[J].Osteoporos Int, 1999, 9(5):461-468.
[12] Cranney A, Guyatt G, Griffith L, et al.Summary of metaanaly ses of therapies for postmenopausal osteoporosis[J]. Endocr Rev, 2002, 23(4):570-578.
[13] 项云霞, 庞小芬, 朱理敏, 等.骨化三醇与阿仑膦酸钠治疗骨质疏松症初步观察[J].实用老年医学,2001, 15(2):81-83.
[14] Hirayama T, Sabokbar A, Athanasou NA.Effect of corticosteroids on human osteoclast formation and activity[J].J Endocrinol, 2002, 175(1):155-163.

[1]	赵阳婷, 陈重阳, 潘斌晶, 吕小羽, 刘靖芳. 三甲胺N-氧化物：骨质疏松治疗的潜在靶点[J]. 中国临床药理学与治疗学, 2023, 28(10): 1161-1167.
[2]	叶森, 陈彦震, 赖丽萍, 钟凌剑, 余长章. 超声与X线引导椎体成形术穿刺进针路径的手术疗效及安全性对比研究[J]. 中国临床药理学与治疗学, 2022, 27(5): 551-557.
[3]	杜尘, 田禾, 曹阳, 王拥军, 张岩. 从内分泌激素探讨多囊卵巢综合征诱发骨代谢异常的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(3): 328-333.
[4]	王梦文, 郭艳, 王重阳, 陶福林, 朱文涛, 韩智莉, 孙念霞, 李泽庚, 汪电雷. 化痰降气胶囊含药血清调控Nrf2/HDAC2改善16HBE细胞糖皮质激素抵抗[J]. 中国临床药理学与治疗学, 2021, 26(12): 1360-1369.
[5]	李静, 马丽娟, 袁圆, 王捷, 郁长治, 赵军. 吸入性糖皮质激素布地奈德相关基因多态性与哮喘疗效的关系[J]. 中国临床药理学与治疗学, 2021, 26(11): 1250-1258.
[6]	俞陈陈，刘树群，刘建龙，曹红，刘雪娇，蔡茜茜. 姜黄素对高血压病大鼠全脑缺血再灌注时海马神经元损伤及皮质酮、SGK1表达的影响[J]. 中国临床药理学与治疗学, 2019, 24(7): 737-743.
[7]	张丹阳，董晓敏，周晓焕，张越，张娟，周合冰. 基于GEO数据库筛查急性淋巴细胞白血病糖皮质激素耐药相关基因[J]. 中国临床药理学与治疗学, 2019, 24(3): 272-277.
[8]	薛骅，鲁丽利，向辉，钱振华. 乌司他丁联合氢化可的松治疗重症脓毒血症休克的疗效及对血清因子的影响[J]. 中国临床药理学与治疗学, 2019, 24(3): 313-317.
[9]	贺筱彬，林小华，刘舜莉，欧焕娇. 血嗜酸性粒细胞水平影响慢性阻塞性肺疾病急性加重患者使用全身糖皮质激素的药物利用评价[J]. 中国临床药理学与治疗学, 2019, 24(1): 89-93.
[10]	卢晓红，王培光. 皮肌炎治疗研究进展[J]. 中国临床药理学与治疗学, 2018, 23(7): 836-840.
[11]	邓祖跃，黄俊俊. 仙灵骨葆联合益生菌对骨质疏松性骨折大鼠的愈合作用[J]. 中国临床药理学与治疗学, 2018, 23(10): 1126-1131.
[12]	喻琴云，苏孝共，包琦瑛，陈晓燕. 白藜芦醇对去卵巢骨质疏松大鼠Wnt/β-Catenin通路的影响[J]. 中国临床药理学与治疗学, 2017, 22(6): 645-649.
[13]	张军，谢艳云，李智，陶立坚. 剪接因子SRp40调控糖皮质激素受体α/β的表达及其对肾病综合征患者糖皮质激素疗效的影响[J]. 中国临床药理学与治疗学, 2017, 22(5): 589-593.
[14]	喻琴云，詹晓峰，黄彦. 刺芒柄花素对去势骨质疏松大鼠P38MAPK/MMP-9信号通路的影响[J]. 中国临床药理学与治疗学, 2017, 22(12): 1371-1376.
[15]	商宏恺，傅爱萍，陈露芳，仝进毅，斯奇. 地塞米松对人胎盘葡萄糖转运功能的作用及机制[J]. 中国临床药理学与治疗学, 2017, 22(11): 1221-1226.